A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

February 18, 2025

Study Completion Date

February 18, 2025

Conditions
Advanced Solid Tumours
Interventions
DRUG

Ceralasertib

Tablets will be administered orally

Trial Locations (18)

10065

Research Site, New York

17522

Research Site, Ephrata

19104

Research Site, Philadelphia

21079

Research Site, Dijon

21231

Research Site, Baltimore

28050

Research Site, Madrid

29572

Research Site, Myrtle Beach

33076

Research Site, Bordeaux

33612

Research Site, Tampa

46202

Research Site, Indianapolis

48109

Research Site, Ann Arbor

54519

Research Site, Vandœuvre-lès-Nancy

69373

Research Site, Lyon

89119

Research Site, Las Vegas

90089

Research Site, Los Angeles

91010

Research Site, Duarte

94115

Research Site, San Francisco

08036

Research Site, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY